Search Result

Pathways Recommended:	MAPK/ERK Pathway

Results for "

Gq pathway

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adrenergic Receptor (1) Akt (1) Cholecystokinin Receptor (1) Cholinesterase (ChE) (1) ERK (1) Free Fatty Acid Receptor (1) GHSR (1) GLP Receptor (1) GSK-3 (1) Leukotriene Receptor (1) mAChR (3) Oxytocin Receptor (1) PACAP Receptor (1) PI3K (1) PKA (1) Protease Activated Receptor (PAR) (2) Reference Standards (1) Serotonin Transporter (1) Succinate Receptor 1 (1) Trace Amine-associated Receptor (TAAR) (2)
By Research Areas:	Cancer (3) Cardiovascular Disease (1) Endocrinology (1) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (10)

By Targets:

5-HT Receptor (3)

Adrenergic Receptor (1)

Akt (1)

Cholecystokinin Receptor (1)

Cholinesterase (ChE) (1)

ERK (1)

Free Fatty Acid Receptor (1)

GHSR (1)

GLP Receptor (1)

GSK-3 (1)

Leukotriene Receptor (1)

mAChR (3)

Oxytocin Receptor (1)

PACAP Receptor (1)

PI3K (1)

PKA (1)

Protease Activated Receptor (PAR) (2)

Reference Standards (1)

Serotonin Transporter (1)

Succinate Receptor 1 (1)

Trace Amine-associated Receptor (TAAR) (2)

By Research Areas:

Cancer (3)

Cardiovascular Disease (1)

Endocrinology (1)

Inflammation/Immunology (2)

Metabolic Disease (2)

Neurological Disease (10)

Inhibitors & Agonists

Peptides

Targets Recommended: Tissue Factor Pathway Inhibitor (TFPI)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-125791

cis-Epoxysuccinic acid 3 Publications Verification	Succinate Receptor 1	Cardiovascular Disease
cis-Epoxysuccinic acid is a succinate receptor (SUCNR1/GPR91) agonist. cis-Epoxysuccinic acid inhibits cAMP levels with an EC₅₀ value of 2.7 μM. cis-Epoxysuccinic acid can be used for the research of cardiovascular system .

HY-107111

GSK1034702	mAChR	Neurological Disease
GSK1034702 is an orally active and allosteric agonist of M1 mAChR (pEC₅₀=8.1) that can cross the blood-brain barrier. GSK1034702 activates the *Gq/11* protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions) .

HY-P6292

KS-133	PACAP Receptor PKA ERK PI3K Akt GSK-3	Neurological Disease Cancer
KS-133 is a bicyclic peptide with VIPR2 antagonistic activity that can cross the blood-brain barrier. KS-133 selectively blocks VIPR2-mediated Gq/Ca, Gs/cAMP, cAMP/PKA/ERK and PI3K/AKT/GSK3β signaling pathways. KS-133 inhibits VIPR2 agonist-induced CREB phosphorylation in the prefrontal cortex of mice. KS-133 shifts the polarization direction of macrophages toward M1. KS-133 attenuates cancer cell proliferation and reduces the cell cycle distribution level at the S-M phase. KS-133 exerts antitumor effects in a mouse model of colorectal cancer. KS-133 reverses cognitive decline in mouse models of psychiatric disorders. KS-133 can be used for research related to schizophrenia, colorectal cancer and breast cancer .

HY-42346

ZH8651	Trace Amine-associated Receptor (TAAR)	Neurological Disease
ZH8651 is an agonist of TAAR1 which can activate both Gs and Gq signal pathway. ZH8651 can used in study schizophrenia .

HY-P5358

YFLLRNP	Protease Activated Receptor (PAR)	Others
YFLLRNP is a biological active peptide. (a partial agonist of PAR-1. YFLLRNP selectively active G12/13 signaling pathway without activating Gq or Gi pathways at low concentrations. YFLLRNP (60 μM))

HY-176921

ONO-2570366	Leukotriene Receptor	Inflammation/Immunology
ONO-2570366 (Compound 11a) is an antagonist of the cysteinyl leukotriene receptors CysLT1R and CysLT2R (IC₅₀ = 14 nM). ONO-2570366 inhibits the binding of LTD₄Gq signaling pathway mediated by receptor activation. ONO-2570366 can be used for the researches of inflammation and immunology, such as asthma .

HY-175515

5-HT2C agonist-11	5-HT Receptor	Neurological Disease
5-HT2C agonist-11 (Compound 1) is an orally active, brain-penetrant and selective 5-HT_2C receptor agonist (EC₅₀=15 nM). 5-HT2C agonist-11 activates the Gq protein signaling pathway, promoting intracellular calcium release. 5-HT2C agonist-11 is promising for research of depression, post-traumatic stress disorder (PTSD) and neuropathic pain .

HY-157955

TAAR1 agonist 1	Trace Amine-associated Receptor (TAAR)	Neurological Disease
TAAR1 agonist 1 (compound 6E) is a potent TAAR1 agonist with a potent TAAR1-Gs/Gq dual-pathway activation property. TAAR1 agonist 1 significantly alleviates MK-801-induced schizophrenia-like cognitive phenotypes .

HY-138951

AY77	Protease Activated Receptor (PAR)	Inflammation/Immunology Cancer
AY77 is a calcium-biased PAR2 agonist. AY77 shows an EC₅₀ of 0.17 and 2 nM in PAR2-mediated the activation in the Gq pathway and recruitment of β-arrestin-2, respectively. AY77 potently induces intracellular Ca ²⁺ release .

HY-121140

AZ1729	Free Fatty Acid Receptor	Metabolic Disease
AZ1729 is a potent free fatty acid 2 receptor (FFA2) activator, acting as a direct allosteric agonist and as a positive allosteric modulator. AZ1729 increases the activity of the endogenously produced short chain fatty acid propionate in G_i-mediated pathways, but not at those transduced by G_q/G₁₁. AZ1729 induces inhibition of isoproterenol-induced lipolysis in mouse adipocytes. AZ1729 also can Induce migration of human neutrophils. AZ1729 can be used for researching the signaling pathways of the physiological roles of FFA2 .

HY-P5017

(Val3,Pro8)-Oxytocin	Oxytocin Receptor	Endocrinology
(Val3,Pro8)-Oxytocin is the Gq-dependent pathway agonist. (Val3,Pro8)-Oxytocin is also a weaker agonist for the β-arrestin engagement and endocytosis toward the oxytocin receptor (OXTR) .

HY-107111A

GSK1034702 hydrochloride	Cholinesterase (ChE) mAChR	Neurological Disease
GSK1034702 hydrochloride is an orally active and allosteric agonist of M1 mAChR (pEC₅₀=8.1) that can cross the blood-brain barrier. GSK1034702 hydrochloride activates the *Gq/11* protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 hydrochloride can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 hydrochloride can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions) .

HY-P1432A

K-(D-1-Nal)-FwLL-NH2 TFA	GHSR	Cancer
K-(D-1-Nal)-FwLL-NH2 TFA is a high affinity and potent ghrelin receptor inverse agonist (K_i values are 4.9 and 31 nM in COS7 and HEK293T cells, respectively). K-(D-1-Nal)-FwLL-NH2 blocks ghrelin receptor-mediated Gq- and G13-dependent signaling pathways.

HY-179721

CCKBR agonist-2	Cholecystokinin Receptor	Neurological Disease
CCKBR agonist-2 (Compound z-44) is a Gi-preferring CCKBR agonist. CCKBR agonist-2 effectively activates the CCKBR-Gi signaling pathway (EC₅₀ = 0.27 nM), but has almost no activity on Gq and Gs signaling pathways. CCKBR agonist-2 shows no significant protective effect in the mouse Alzheimer's disease model, proving that the simple activation of the Gi signal pathway does not play a dominant role in the improvement of cognitive function .

HY-145156

CHU-128	GLP Receptor	Metabolic Disease
CHU-128 is an effective and selective GLP-1R agonist. CHU-128 exhibits strong signal specificity and can activate the Gs/cAMP pathway, but it cannot activate the Gq/calcium signal, ERK phosphorylation, or recruit β-inhibitory proteins. CHU-128 can be used for research on type 2 diabetes .

HY-107111R

GSK1034702 (Standard)	Reference Standards mAChR	Neurological Disease
GSK1034702 (Standard) is the analytical standard of GSK1034702 (HY-107111). This product is intended for research and analytical applications. GSK1034702 is an orally active and allosteric agonist of M1 mAChR (pEC₅₀=8.1) that can cross the blood-brain barrier. GSK1034702 activates the Gq/11 protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions) .

HY-181878

Z8779877149 Z7149	Serotonin Transporter Adrenergic Receptor 5-HT Receptor	Neurological Disease
Z8779877149 (Z7149) is a blood-brain barrier-permeable multi-target ligand that targets SERT (K_i=198 nM), α2A adrenergic receptor (K_i=180 nM; EC₅₀=440 nM) and 5-HT_2A receptor (EC₅₀=172 nM, E_max=76%). Z8779877149 inhibits 5-HT reuptake and activates G_i and Gq protein signaling pathways, respectively. Z8779877149 effectively alleviates pain responses as well as depression- and anxiety-like behaviors, while exhibiting favorable safety without inducing sedation or motor impairment. Z8779877149 is available for the research of pain, depression and anxiety disorders .

HY-186170

R-MDMA	5-HT Receptor	Neurological Disease
R-MDMA, 4-methylenedioxymethamphetamine (MDMA) isomer, is a 5-HT2A/5-HT2C receptor antagonist with an IC₅₀ of 629 and 61.4 nM. R-MDMA promotes cortical neuron growth. R-MDMA facilitates fear extinction learning and produces antidepressant-like effects in preclinical rodent models. R-MDMA can be used for the researches of post-traumatic stress disorder and depression .

Cat. No.	Product Name	Target	Research Area